FDA again issues complete response letter to Recro Pharma for intravenous meloxicam

Recro Pharma on Friday disclosed that it has received a second complete response letter from the FDA concerning its filing seeking approval of an intravenous formulation of the non-opioid drug meloxicam to manage moderate-to-severe pain.

CEO Gerri Henwood remarked "we remain steadfast in our belief that [intravenous] meloxicam holds significant potential as a treatment option for moderate-to-severe pain in multiple clinical settings," adding that the company is "[working] closely with the FDA to determine the best path forward to obtain approval." 

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.